How does combined HRT such as Kliofem affect breast cancer risk?

Combined oestrogen–progestagen HRT such as Kliofem increases breast cancer risk with duration of use, becoming apparent after about 3 (1–4) years; excess risk decreases after stopping, but return to baseline depends on prior use duration, and risk may persist for 10 years or more after use exceeding 5 years.